Subversion of the plasminogen activation system is implicated in the virulence of group A streptococci (GAS). GAS display receptors for the human zymogen plasminogen on the cell surface, one of which is the plasminogen-binding group A streptococcal M-like protein (PAM). The plasminogen binding domain of PAM is highly variable, and this variation has been linked to host selective immune pressure. Site-directed mutagenesis of full length PAM protein from an invasive GAS isolate was undertaken to assess the contribution of residues in the a1 and a2 repeat domains to plasminogen binding function. Mutagenesis to alanine of key plasminogen binding lysine residues in the a1 and a2 repeats ( 102 and His 115 in both the a1 and a2 repeat domains of PAM can mediate high affinity plasminogen binding. These data suggest that highly conserved arginine and histidine residues may compensate for variation elsewhere in the a1 and a2 plasminogen binding repeats, and may explain the maintenance of high affinity plasminogen binding by naturally occurring variants of PAM.
The Gram positive bacterium Streptococcus pyogenes (group A streptococcus, GAS) 1 is responsible for a wide variety of skin and mucosal infections in humans. Current estimates indicate that approximately 1.78 million new cases of severe streptococcal infection occur each year (1) . A key feature of invasive GAS infections is the ability of the organism to migrate from cutaneous and mucosal surfaces to deep tissue sites, resulting in severe invasive disease. The binding and activation of plasminogen by GAS has been implicated in the pathogenesis of this organism (2).
Plasminogen is a single chain glycoprotein found in plasma and extracellular fluids at concentrations of approximately 2 μM (3). Cleavage of plasminogen at a single site (Arg
-Val

561
) by specific plasminogen activators results in the formation of the twochain plasmin molecule, which contains a serine protease active site in the C-terminal region (4) . Human plasminogen can also be activated to plasmin by the GAS protein streptokinase, as part of a highly species specific plasminogen/streptokinase activator complex (2) . Plasmin has the ability to degrade fibrin clots, connective tissue and the extracellular matrix (3, 4) . Thus activation of this proteolytic system by GAS may have significant pathological consequences in the host (5).
Isolated initially from M53 serotype GAS, the plasminogen-binding group A streptococcal M-like protein (PAM) is a 42 kDa molecule which binds both plasmin and plasminogen directly and with high affinity (K d ~ 1 nM) (6) . A newly developed model of GAS infection using mice expressing a human plasminogen transgene indicates that plasminogen plays a critical role in GAS infection, with a significant increase in mortality observed in transgenic mice when compared to wild type littermate control mice (5) . Additionally, the PAM-positive GAS isolate AP53 exhibited a 60% increase in mortality in transgenic mice when compared to wild type littermates, and a PAM negative isogenic mutant of this strain showed only minimal virulence in both wild type and human plasminogen transgenic murine backgrounds (5) . Thus, it appears that for a subset of GAS isolates, the ability of PAM to focus plasminogen at the GAS cell surface is crucial for virulence.
The major plasmin(ogen)-binding site of PAM is located in the N-terminal variable region of the protein, and is comprised of two characteristic tandem repeats designated a1 and a2. Similar binding motifs have been identified in M-like proteins of other GAS isolates associated with skin infection (6, 7) . PAM has been implicated in the establishment of GAS skin infections such as impetigo, and the PAM genotype is almost exclusively associated with the chromosomal emm pattern D, which is considered a genetic marker for skin tropic GAS (7) (8) (9) . However, in the Northern Territory of Australia, where streptococcal skin infection is endemic and high rates of invasive infection such as bacteraemia have been reported (10) , PAM positive GAS are associated with a variety of disease states (11) . The plasminogen binding domain of PAM has been shown to be highly variable, however, this diversity does not abrogate plasminogen binding by naturally occurring PAM variants (12) . This finding may, in part, be due to the conservation of key amino acid residues within the plasminogen binding domain (11, 12) . Plasmin(ogen) is known to interact with its ligands via preformed lysine binding-sites within the Nterminally located triple-disulfide bonded kringle domains (4). Kringles 1, 4 and 5 display the highest affinity for lysine-based ligands, with kringle 2 displaying the weakest affinity (13) . PAM lacks the typical Cterminal lysine residues characteristic of many plasminogen receptors. Rather, internal lysine residues in the a1 and a2 repeat regions of PAM (Lys 98 and Lys
111
) are thought to mediate binding to kringle 2 of plasminogen (14) . Early reports suggested that Lys 98 of the a1 repeat contributed the majority of the plasminogen binding ability of PAM (14) . However, studies involving a polypeptide designated VEK-30 and a recombinant kringle 2 modified to contain a high affinity lysine binding site, highlighted a potential role for internal His
102
, Arg 101 and Glu 104 residues within the a1 repeat in this interaction (15, 16) . VEK-30 is comprised of the six residues preceding the a1 repeat, the entire a1 repeat, together with the first ten residues of the a2 repeat of PAM (17) . The relative contribution to binding by residues within the a1 and a2 repeat of the full length PAM protein to plasminogen has not been characterised.
Here, we have undertaken site-directed mutagenesis studies on the PAM molecule and defined residues involved in the interaction with plasminogen. These studies highlight the important contribution of multiple arginine and histidine residues within both the a1 and a2 plasminogen binding domains and may explain the capacity of naturally occurring PAM variants to maintain high affinity plasminogen binding despite considerable variation observed in the plasminogen binding repeats.
MATERIALS AND METHODS
Bacterial strains and culture methodsEscherichia coli TOP10 containing pGEX2T-PAM NS13 expression plasmids were grown on Luria Bertani (LB) agar plates or cultured in LB broth supplemented with ampicillin (100 μg/ml) as described previously (18) . Plasmid DNA was extracted for PCR and DNA sequence analysis using the Wizard ® Plus SV DNA purification kit (Promega, USA).
Site-directed mutagenesis -The PAM gene from streptococcal strain NS13 (PAM NS13 GenBank™ AY351851), which is identical to the prototype PAM sequence in the a1 and a2 repeat domain, had previously been cloned into the expression vector pGEX2T (12) . To assess the role of specific binding-site residues in the interaction of PAM with plasminogen, site-specific mutations were introduced into the PAM NS13 binding site. The wild type construct (100 ng) was used as template DNA to create site-directed mutants with the QuickChange™ site-directed mutagenesis kit (Stratagene, USA). PCR reactions consisted of 1x Pfu reaction buffer (Stratagene, USA), 0.25mM dNTPs (Boehringer Mannheim, Germany), 2.5 U of Pfu Ultra polymerase (Stratagene, USA), and 125 ng of each primer, made up to a volume of 50 μl with dH 2 O. Oligonucleotide Primers (Sigma-Aldrich) were designed as per the manufacturers instructions (Stratagene, USA). In general, primers consisted of sequence encoding the desired mutation, flanked on either side by fifteen nucleotides of wild type sequence. The specific primer sequences are given in Table  1 , with the introduced mutations underlined. For site-directed mutants containing more than two mutations not encoded by a single primer, alanine residues were sequentially introduced using previously mutated DNA as a template. Following an initial denaturation step (95°C, 30 sec), PCR cycling parameters consisted of sixteen cycles of 95°C for 30 sec, 55°C for 1 min and 68°C for 10 min. An additional 7 min extension at 55°C was then performed. PCR was conducted with a Cooled Palm 96 thermocycler (Corbett Research). Nonamplified template DNA was removed by incubation of reactions for 1 h at 37°C following the addition of Dpn I (10 U/ 50 μl reaction). E. coli TOP10 (Invitrogen, USA) were transformed with 150 ng of Dpn I digested PCR product using standard procedures (18) .
DNA sequence analysis, expression and purification of recombinant M proteins -DNA sequence analysis was used to verify introduced mutations and confirm the absence of random mutations in site-directed mutants. DNA sequence analysis was performed using the primers listed in Table 1 , and sequence reactions undertaken using terminator ready reaction mix (PE Applied Biosystems, USA). DNA sequencing gels were prepared as per the manufacturers instructions and electrophoresed using an Applied Biosystems 3130 X Genetic Analyser (Applied Biosystems, USA). Sequence data was analysed using ABI Prism™ DNA sequencing analysis software (Perkin Elmer, USA).
Recombinant proteins were expressed and purified essentially as described previously (12, 19) , from 1 L E. coli cultures, using glutathione agarose (Sigma-Aldrich, USA) and native Ni-NTA agarose (Qiagen, Germany) affinity chromatography. Prior to elution from the glutathione agarose column, the GST tag was removed from the Nterminus of recombinant fusion proteins by the addition of one column volume of thrombin solution (1 U thrombin/μl, PBS pH 8.0). The column was incubated for 5 h at room temperature and the cleaved recombinant protein eluted in PBS (pH 8.0). Each step of the protein purification process was monitored by 12% SDS-polyacrylamide gel electrophoresis (PAGE) analysis (20) , with protein visualised using Coomassie R 250 staining.
Circular dichroism spectroscopy -To examine potential variation in protein secondary structure as a result of site-directed mutagenesis, far UV Circular dichroism (CD) spectra were obtained for both wild type and mutant recombinant PAM proteins. CD spectra were acquired using a Jasco J-810 Spectropolarimeter (Jasco, Canada) at room temperature. CD spectra data was recorded from 190 -250 nm in a 1 cm pathlength cell containing 1.5 ml of protein solution at a concentration of 0.04 mg/ml in 10 mM sodium phosphate buffer (pH 7.4). Recorded data represents the average of six scans, corrected for buffer baseline. Molar residue ellipticity ([θ]) was calculated using the following formula:
[θ] = θ × 100 × Molecular weight / concentration (mg/ml) × distance × Number of amino acids (21) . The percentage of α-helix was estimated from the ellipticity at 222 nm using the following formula: % α-helix = -(θ 222 nm -4,800)/45,400 (22).
Plasminogen purification and labeling -Gluplasminogen was purified from human plasma using lysine Sepharose-4B affinity chromatography as described previously (12, 23) .
Purified plasminogen was biotinylated by the addition of 10% (v/v) 1 M NaHCO 3 (pH 9), and a 40 molar excess of biotin-X-NHS in dimethyl sulfoxide (SigmaAldrich, USA). The reaction was incubated at 4°C overnight with mixing. Free biotin was separated from biotinylated plasminogen by PD-10 gel filtration chromatography (Amersham Biosciences, USA) (12) .
Plasminogen binding analysis -Solid phase plasminogen binding assays were performed in order to assess the impact of introduced mutations on protein function essentially as previously described (12) . Ninety-six well microtitre plates (Greiner Bio-one, Germany) were coated with 150 nM recombinant protein (50 μl in 0.1 M NaHCO 3 ) at 4°C overnight. Following three washes with PiNT (50 mM Na 2 HPO 4 , 150 mM NaCl, 0.05% Tween-80, pH 7.5), plates were blocked with 50 μl of blocking solution (1% skim milk powder, PiNT) for 1 h at 37°C. Wells were washed as above, and 500 nM biotinylated gluplasminogen was diluted in a three-fold titration across the plate with blocking buffer, in the presence or absence of a 50 fold molar excess of unlabelled glu-plasminogen. Plasminogen was allowed to bind to immobilised proteins for 2 h at room temperature.
For competition assays, decreasing concentrations of unlabelled fluid phase wild type PAM NS13 (25 μM-0.14 nM) were allowed to compete with immobilised proteins for binding to biotinylated gluplasminogen. Competitor was titrated threefold across the microtitre plate prior to the addition of biotinylated glu-plasminogen to all wells, at a final concentration of 500 nM. The assay was incubated for 2 h at room temperature. Following the plasminogen incubation step, microtitre plates were washed three times, and 50 μl of neutravidin conjugated to horse radish peroxidase (Progen, Australia) diluted 1:5000 with blocking solution was added to all wells and incubated for 2 h at room temperature. After five washes with PiNT, the reactions were developed by the addition of 50 μl o-phenylenediamine (Sigma-Aldrich, USA) substrate (8 mM Na 2 HPO 4 pH5.0, 2.2mM o-phenylenediamine, 3% H 2 O 2 ). Colour development was stopped by the addition of 50 μl of 10 M hydrochloric acid, and the plates were read at 490 nm using a Spectramax 250 plate reader (Molecular Devices, USA).
Data was normalised against the highest and lowest absorbance value for each assay, and non-linear regression analysis performed using GraphPad ® Prism (v4.00, GraphPad software, CA). For the calculation of equilibrium binding dissociation constants (K d ), a one versus two site binding analysis was conducted and the best-fit curve fitted to the data. For competition experiments, a one-site competition curve was fitted to the data from which the effective concentration of competitor required to inhibit binding by 50% (EC 50 ) was calculated.
Statistical analysis -For plasminogen binding experiments, a one-way ANOVA was initially used on all data, followed by an unpaired t-test with Welsch's correction to determine if there was any significant difference in the K d values for plasminogen binding by PAM mutants and PAM NS13 .
RESULTS
The gene encoding wild type PAM NS13 shares 100% identity with the prototype PAM sequence in the a1 and a2 repeat domain responsible for the interaction with plasminogen (11) . In order to assess the role of specific binding site residues in the interaction of PAM NS13 with plasminogen, a number of site-directed mutants were constructed in which the residues of interest were replaced with alanine. The binding site sequences of the five constructed mutants are shown in Fig. 1A . The presence of introduced mutations was verified by DNA sequence analysis. Following expression in E. coli, recombinant proteins of approximately 40 kDa in size were purified using glutathione-agarose and Ni-NTA agarose affinity chromatography (Fig. 1B) .
The impact of mutations in the a1 and a2 repeat domains of PAM NS13 on protein structure were analysed using far UV CD spectroscopy. All proteins used in this study were found to have a CD emission spectrum characteristic of α-helical coiled proteins (24) , displaying two characteristic minima at approximately 210 nm and 220 nm, and a maximum peak at 190 nm (Fig. 2) . This is similar to the CD spectra of other streptococcal M proteins, which are coiledcoil α-helical proteins (22). Thus, even after mutagenesis these proteins appear to maintain an α-helical secondary structure. Additionally, for all proteins the two minima are of a similar magnitude, which is indicative of coiled-coil proteins (25). Percent α-helicity ranged from 27% to 44% (Table 2 ). CD analysis of other streptococcal M proteins has found them to contain between 23% and 70% α-helix (22,26). PAM NS13 has previously been shown to interact with glu-plasminogen with high affinity (K d ~ 1 nM) (12) . To determine the impact of the introduced mutations in the PAM NS13 binding site on plasminogen binding, solid phase binding assays were performed utilising biotinylated glu-plasminogen. The recombinant PAM mutants bound plasminogen in a dose-dependant fashion, and saturable binding was achieved with 500 nM plasminogen for 3 of the 5 mutant proteins after 2 h (Fig. 3) . Non-linear regression analysis was used to determine the affinity of each recombinant protein for glu-plasminogen (Table 2) . Equilibrium dissociation constants (K d ) were calculated using a best-fit non-linear regression curve. The following site-directed mutants where residues were replaced with alanine, PAM NS13 115 ], indicating that the arginine and histidine residues in both repeat domains are critical residues in the interaction of PAM with plasminogen.
To further explore the contribution of these residues to the interaction with plasminogen, competition binding experiments were performed. The effective concentration of competitor required to inhibit plasminogen binding by 50% (EC 50 ) was determined by fitting a one-site competition curve (Fig. 4) necrotising fasciitis and streptococcal toxic shock-like syndrome. The exact mechanisms of GAS invasive infection have yet to be fully explained, however one hypothesis involves the interaction of GAS with the host plasminogen activation system. Four GAS plasminogen binding proteins have been described in the literature, as well as the secreted plasminogen activator streptokinase (2, (27) (28) (29) . The multiplicity of potential virulence factors associated with S. pyogenes that interact with the plasminogen activation system necessitates a deeper understanding of the relationship of GAS with plasminogen.
PAM is a cell surface exposed, high affinity plasminogen receptor expressed by GAS associated with a variety of disease states, and appears to play an integral role in the plasminogen-dependant virulence of PAM positive GAS. In a recent study, it was shown that elimination of PAM dependant plasminogen binding by GAS significantly reduced mortality in mice expressing the human plasminogen transgene (5). Furthermore, whilst the plasminogen binding domain of PAM is highly variable, this variation does not appear to significantly impact on the high affinity interaction of PAM ) residues in both the a1 and a2 repeat was required to fully abrogate plasminogen binding suggests that both repeats are able to mediate high affinity interactions with plasminogen. Residues Arg 101 and His 102 of the a1 repeat of PAM have been shown to make numerous saltbridge and hydrophobic electrostatic interactions with recombinant kringle 2, forming a pseudoligand similar to the lysine analogue ε-amino caproic acid (16) . It is thus likely that the corresponding residues Arg 114 and His 115 in the a2 repeat interact with plasminogen in a similar fashion.
The decrease in plasminogen binding by sitedirected mutants reported here does not appear to be due to loss of secondary structure, as all site-directed mutants displayed CD spectra characteristic of coiled-coil alpha-helical proteins, similar to that of the wild type PAM NS13 . The percent α-helicity for mutants reported here was between 27% and 44%. CD analysis of other streptococcal M proteins has found them to contain between 23% and 70% α-helix (22, 26). However, the spectra for all α-helical proteins are not identical due to the small effect of non-aromatic side chains on the rotary strength of the peptide bond, and occasional helix distortions (24) . It has also been shown that the α-helical structure of the peptide VEK-30, representative of the a1 repeat of PAM, increases from 25% to 75% upon binding to kringle 2 of plasminogen (16) . It is possible that a similar structural shift could occur in the full length PAM protein. No correlation was seen between percent α-helicity and plasminogen binding function, suggesting that any secondary structure changes have had only a minor influence on the differences in plasminogen binding described here.
We have recently shown that whilst the plasminogen binding domain of PAM is Recent findings that the acquisition of plasminogen by S. pyogenes may be crucial for the virulence of certain strains of GAS, and the ability of multiple GAS proteins to facilitate this process, necessitates a deeper understanding of the mechanisms via which certain GAS proteins interact with plasminogen. This study highlights for the first time the importance of highly conserved arginine ( (12) . In these naturally occurring PAM variants, the Arg and His residues in both a1 and a2 repeat domains are highly conserved (11) . Interestingly, in this study, a loss of plasminogen binding was only observed following simultaneous mutation of both the Arg 101 and His 102 residues in the a1 repeat, and the Arg 114 and His 115 residues in the a2 repeat. Therefore, conservation of Arg and His residues in either repeat domain may compensate for variation elsewhere in the binding repeats, and explain the maintenance of high affinity plasminogen binding by naturally occurring variants of PAM. 
